Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Inclusion Criteria:

• Patients with pathology confirmed newly diagnosed World Health Organization (WHO)grade IV glioma

• Karnofsky performance status (KPS) ≥ 60

• Patients must have recovered from the effects of surgery per treating physician'sjudgment; there must be a minimum of 21 days from the day of surgery to the day ofprotocol treatment; for core or needle biopsy, a minimum of 14 days must haveelapsed prior to the day of protocol treatment

• Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3

• Platelets ≥ 100,000 cells/mm^3

• Hemoglobin ≥ 9.0 g/dl

• Creatinine clearance > 30 mL/min

• Bilirubin < 2.0 mg/dL

• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit ofnormal range

• Women of childbearing potential must have a negative beta-human chorionicgonadotropin (HCG) pregnancy test documented within 14 days prior to registration

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry andfor 4 months after last dose of temozolomide

• Is able to have magnetic resonance imaging (MRI) with contrast of the brain

• All subjects must be able to comprehend and sign a written informed consentdocument. If the subject can comprehend the informed consent but is unable to sign,a LAR may sign the written informed consent document.

Exclusion Criteria:

• Infratentorial disease (defined as glioblastoma [GBM] derived from cerebellum orbrainstem)

• Implanted pacemaker, defibrillator or deep brain stimulator, or documentedclinically significant arrhythmias

• A skull defect (such as, missing bone with no replacement)

• Women of childbearing potential who are pregnant or breastfeeding

• Evidence of increased intracranial pressure (midline shift > 5 mm, clinicallysignificant papilledema)

• Serious medical or psychiatric illness likely to interfere with participation inthis clinical study, in the opinion of the investigator

• Prior radiation treatment to the brain

• Prior treatment with temozolomide

• Known hypersensitivity to conductive hydrogels like the gel used onelectrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes

• Known active collagen vascular disease